A Phase 1a Open-Label Study to Assess the Safety and Pharmacokinetics of a Single ZMapp Administration in Healthy Adult Volunteers

Trial Profile

A Phase 1a Open-Label Study to Assess the Safety and Pharmacokinetics of a Single ZMapp Administration in Healthy Adult Volunteers

Recruiting
Phase of Trial: Phase I

Latest Information Update: 22 May 2017

At a glance

  • Drugs Porgaviximab (Primary)
  • Indications Ebola virus infections
  • Focus Adverse reactions; Pharmacokinetics
  • Most Recent Events

    • 26 Jan 2017 Planned End Date changed from 31 May 2017 to 31 Jan 2025.
    • 26 Jan 2017 Planned primary completion date changed from 31 May 2017 to 31 Jan 2025.
    • 20 Jan 2017 Planned End Date changed from 1 May 2017 to 31 May 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top